Diabetes Research Centre, University of Leicester, Leicester, U.K.
National Institute for Health Research, Leicester Biomedical Research Centre, Leicester, U.K.
Diabetes Care. 2022 Nov 1;45(11):2749-2752. doi: 10.2337/dc22-0888.
Sodium-glucose cotransporter 2 inhibitors (SGLT2i) and glucagon-like peptide 1 receptor agonists (GLP-1RA) reduce body weight and improve cardiometabolic health, but their effect on physical activity is unknown.
We pooled data (n = 148) from three randomized trials to investigate the effect of empagliflozin (SGLT2i) and liraglutide (GLP-1RA), in comparison with sitagliptin (dipeptidyl peptidase 4 inhibitor) and dietary therapies, on accelerometer-assessed physical activity.
Liraglutide (mean -1,144 steps/day; 95% CI -2,069 to -220), empagliflozin (-1,132 steps/day; -1,739, -524), and sitagliptin (-852 steps/day; -1,625, -78) resulted in reduced total daily physical activity after 6 months (P < 0.01 vs. control). Moderate- to vigorous-intensity physical activity was also reduced. Dietary interventions led to no change or an increase in physical activity.
The initiation of all glucose-lowering therapies was associated with reduced physical activity, warranting further investigation.
钠-葡萄糖共转运蛋白 2 抑制剂（SGLT2i）和胰高血糖素样肽 1 受体激动剂（GLP-1RA）可减轻体重并改善代谢健康，但它们对身体活动的影响尚不清楚。
我们汇总了三项随机试验的数据（n=148），以研究恩格列净（SGLT2i）和利拉鲁肽（GLP-1RA）与西他列汀（二肽基肽酶 4 抑制剂）和饮食疗法相比，对加速度计评估的身体活动的影响。
利拉鲁肽（平均减少 1144 步/天；95%CI-2069 至-220）、恩格列净（-1132 步/天；-1739，-524）和西他列汀（-852 步/天；-1625，-78）导致 6 个月后总日常身体活动减少（与对照组相比，均 P < 0.01）。中等至剧烈强度的身体活动也减少了。饮食干预没有导致身体活动的变化或增加。
所有降低血糖疗法的起始均与身体活动减少相关，这需要进一步研究。
